Condition

MSI-High

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting3

Common interventions8

Lead sponsors shown4

Clinical trials

4 shown

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyNCT06362369 · 2024-08-23

RECRUITING

177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsNCT06305962 · 2024-06-03

RECRUITING

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067NCT04787042 · 2021-08-06

RECRUITING

Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical RespondersNCT05286294 · 2022-06-28

ACTIVE_NOT_RECRUITING

Common interventions

177Lu-RAD204DRUG1 AlintegimodDRUG1 Fecal Microbiota Transplant (FMT)BIOLOGICAL1 IpilimumabDRUG1 NivolumabDRUG1 Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]BIOLOGICAL1 pembrolizumabBIOLOGICAL1 ST-067BIOLOGICAL1

Leading sponsors

7 Hills Pharma, LLC1 Oslo University Hospital1 Radiopharm Theranostics, Ltd1 Simcha IL-18, Inc.1

Trial status mix

RECRUITING3

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE23

PHASE12

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.